alexa Management of Hepatotoxicity in HIV-Infected Patients Treated with Combined Antiretroviral Therapy (cART): A Retrospective Cohort Study in Tianjin, China
ISSN 2155-6113
Journal of AIDS & Clinical Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Management of Hepatotoxicity in HIV-Infected Patients Treated with Combined Antiretroviral Therapy (cART): A Retrospective Cohort Study in Tianjin, China

Ping Ma1,3#, Jing Qian1#, Liying Gao1, Defa Zhang1, Aiping Yu1, Chunting Qiu1 and Min Wei2*

1The Tianjin Second People’s Hospital, Tianjin, China

2School of Medicine, Nankai University, Tianjin, China

3Tianjin Institute of Liver Disease, Tianjin, China

#Authors contributed equally

Corresponding Author:
Min Wei
School of Medicine
Nankai University
No.94 Weijin Road, Tianjin, China
Tel: 0086-022-23509579
E-mail: [email protected]

Received date: August 11, 2017; Accepted date: August 18, 2017; Published date: August 25, 2017

Citation: Ma P, Qian J, Gao L, Zhang D, Yu A, et al. (2017) Management of Hepatotoxicity in HIV-Infected Patients Treated with Combined Antiretroviral Therapy (cART): A Retrospective Cohort Study in Tianjin, China. J AIDS Clin Res 8:723. doi:10.4172/2155-6113.1000723

Copyright: © 2017 Ma P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of AIDS & Clinical Research

Abstract

Background: Liver diseases are among the most frequent causes of non-AIDS-related deaths in human immunodeficiency virus (HIV)-infected patients due to hepatitis B or C virus co-infections, and/or the toxicity of longterm treatment of some antiviral drugs. There are few cohort studies reported in China. Methods: All data from the clinic HIV/AIDS patients in the database of Tianjin Second People’s Hospital, a branch of the National Free Antiretroviral Treatment Program database, from April 1, 2010 to March 31, 2016 were retrospectively assessed and analyzed. Results: We analyzed 2270 HIV-positive, hepatitis B virus (HBV-), hepatitis C virus (HCV-) negative patients, who received cART and followed for 13334.8 person-years. A total of 67 patients (3.0%, or 5.0 per 1000 person-years) died of non-liver-related causes. The incidence of liver-related deaths in persons without HCV or HBV co-infections was zero percent during follow-up. Only 30 cases (1.3% or 2.2 per 1000 person-years) developed hepatotoxicity, but liver function of these patients improved after changing cART regimens. Conclusion: cART-related hepatotoxicity can be well-controlled and managed by modifying the therapeutic regimens. Liver-related mortality in HIV-positive, HBV-, HCV-negative patients is currently zero percent in Tianjin, China.

Keywords

Hepatotoxicity; Combined antiretroviral therapy; HIV infection; Cohort study

Abbreviations

HIV: Human Immunodeficiency Virus; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; LEE: Liver Enzyme Elevation; MSM; Men who have Sex with Men; ALT: Alanine Transaminase; AST: Aspartate Transaminase; TBIL: Total Bilirubin; EFV: Efavirenz; 3TC: Lamivudine; AZT: Zidovudine; D4T: Stavudine; NVP: Nevirapine; TDF: Tenofovir

Introduction

China experienced sporadic reports in 1980s of HIV/AIDS epidemic. An outbreak in intravenous drug users (IDUs) in Yunnan province was reported in 1989 [1]. In the mid-1990s, another outbreak was reported among blood donors in central China, in the Henan and Anhui provinces. Since the late of 1990s and the early of 2000s, HIV infection has grown rapidly and has spread through out all of China [1,2]. HIV transmission also gradually shifted from intravenousdrug use to homosexual or heterosexual contact. In recent years, the prevalence of HIV infection in men who have sex with men (MSM) is rapidly increasing in the largest cities, such as Beijing, Shanghai and Tianjin [1-4]. Tianjin city is a large city, one of the four cities governed directly by central government in China. Tianjin, facing Bohai Gulf, is the eastern door of capital Beijing. All of the HIV/AIDS patients in Tianjin were treated and followed in our hospital, The Tianjin Second Peoples’ Hospital (former Tianjin Infectious Disease Hospital). All of HIV-positive cases found in other hospitals in Tianjin and nearby areas were transferred to our hospital. This study will report the Tianjin’s HIV/AIDS cohort.

In 2003, the Chinese government launched the China National Free Antiretroviral Therapy Program, which continues to offer anti-retroviral agents free of charge to Chinese HIV/AIDS patients [3,4]. This program makes it easier for these patients to receive modern combined antiretroviral therapy (cART). The cART has been shown to significantly reduce the mortality of HIV/AIDS, transforming a once fatal disease into one that is more aptly described as chronic, but manageable disease. This progress, however, comes with new challenges. Side effects of cART have emerged as a major issue for HIV/AIDS treatment, and the management of anti-retroviral toxicity becomes a key focus in patient care. One of the side effects of antiretroviral agents is hepatotoxicity [5,6]. On the other hand, hepatitis virus co-infection, the great concern in Chinese HIV/AIDS infected patients, even worsen the effects of hepatotoxicity and further complicate the clinical management. The Data Collection on Adverse Events of Anti-HIV Drug (D:A:D) cohort study and the Euro SIDA observational cohort study showed that liver diseases are among the most frequent causes of non-AIDS–related deaths in HIV-positive patients [7- 11]. Many deaths were related to hepatitis B virus (HBV-) or hepatitis C virus (HCV-) or both co-infections. One study from China also reported the mortality was higher in patients with triple infection or HCV-co-infection than those with mono-HIV-infection [3]. However, there is little research examining cART-related hepatotoxicity in the absence of HBV or HCV co-infection in HIV-infected individuals in China.

The first aim of this study was to estimate the risk of hepatotoxicity of cART in the absence of HBV or HCV co-infection in HIV-infected people, and to define other potential risk factors that may influence hepatotoxicity in this population. Secondly, we attempted to describe the effects of continuation or modification of the cART regimen according to the marker liver enzyme elevation (LEE) among these patients. Based on our results, we propose a feasible plan for the management of cARTrelated hepatotoxicity in such a population.

Patients and Methods

Study population

China maintains a network known as the National Free Antiretroviral Treatment Program database, which is established and managed by the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC). We assessed all data from the database of The Tianjin Second People’s Hospital, a branch of this network, from April 1, 2010 to March 31, 2016 (data downloaded on April 16, 2016). All available data were collected, including patients' medical records, age, gender, routes of transmission, prescribed initial and subsequent cART regimens.

HIV infection status was based on positive HIV screening ELISA tests from two peripheral blood samples and confirmed by western blot. HIV test sites were certified by the National AIDS Reference Laboratory at China CDC. A diagnosis of HCV was given to patients who were seropositive for HCV or positive for HCV RNA. HBV diagnosis was assigned to patients who were positive for hepatitis B surface antigen, hepatitis B E antigen, hepatitis B core antibodies, or HBV DNA during the study period. Patients with chronic HCV infections or chronic HBV infections were excluded from this study. Patients with unknown HBV or HCV status were also excluded. The lost patients during followup were not included in this study. Severe alcohol use was defined according to the WHO definition of alcohol consumption, which uses >40 g/d in females and >60 g/d in males as cut-off values. Patients who were older than 18 years, treatment-naive, and started a standard cART regimen containing two nucleoside and one non-nucleoside reversetranscriptase inhibitors (NRTIs and NNRTIs, respectively, which is called first line regimen) were eligible for this study. All patients in this study were treated naive, but not all were newly diagnosed.

Liver enzyme elevation (LEE) was defined as elevation of liver enzyme than normal values. In this study, the normal values of alanine transaminase (ALT) and aspartate transaminase (AST) are both 0~40 U/L. The normal value of total bilirubin (TBIL) is 1.7~17.1 μmol/L. According to Chinese National guideline of HIV/AIDS therapy, hepatotoxicity was also graded as 1, 2, 3 and 4 [12]. Grade 1 of hepatotoxicity was defined as ALT and/or AST and/or TBIL < 3 times of upper limit of normal (ULN); Grade 2 was ≥ 3 and <5 times of ULN; Grade 3 was <10 and ≥ 5 times of ULN; Grade 4 was ≥ 10 times ULN.

Statistical analysis

The data was input into the SPSS software and analyzed. To compare the difference before and after cART regimens, Student T test or nonparametric test- Wilcoxon test were applied accordingly.

Role of the funding source

The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The author had full access to all data used in the study and had final responsibility over the decision to submit for publication. Written informed consent was obtained from each patient included in the study and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.

Results

Demographic and clinical characteristics of enrolled patients

We collected data for all patients enrolled from April 1, 2010 to March 31, 2016 in The Tianjin Second People’s Hospital. Of total 2532 participants followed for 6 years, 115 patients (4.5%) were HCV positive, 121 (4.8%) were HBV positive, 14 (0.06%) had triple infection and 12 patients (0.05%) were HBV or HCV status unknown at the enrollment or during follow-up. The rest were all HBV and HCV negative (Figure 1). A total of HBV and HCV negative and HIV positive 2270 participants were included in this study and followed 13334.8 person-years. Among them, only 30 cases (1.3% or 2.2 per 1000 personyears) developed hepatotoxicity. Another 67 patients (3.0% or 5.0 per 1000 person-years) died of non liver-related diseases. However, nobody died of liver-related diseases. Thus, the incidence of liver-related deaths in persons without HCV or HBV was zero percent during follow-up. The non-liver related diseases include Pneumocystsis carinii pneumonia (PCP), cryptococcal encephalitis, tuberculous meningitis, etc.

Figure 1: Patient flowchart.

The characteristics of 30 patients who developed hepatotoxicity are listed in Table 1. Compared to 2240 patients who used the same cART regimens in the hospital, only these 30 cases developed hepatotoxicity. Our study focused on these 30 patients. The average age of these patients were 45 years (Table 1). Seventeen patients (56.67%) became infected with HIV by homosexual contact, 7 patients (23.33%) by heterosexual contact and 4 patients (13.33%) by intravenous drug use (IDU).

Variable Value %
All 30 100.00
Gender
 Male 30 100.00
Age (years)
 20-30 5 16.67
 30-40 6 20.00
 40-50 9 30.00
 50-60 8 26.67
 60- 2 6.67
Age (mean ± SD) 43.53 ± 12.11
Routes of transmission
 Homosexual 17 56.67
 Heterosexual  7 23.33
 Intravenous drug use  4 13.33
 Unknown  2  6.67
Years of follow upmean ± SD) 2.95 ± 1.60
Initial regimen
 EFV+3TC+AZT 7 23.33
 EFV+3TC+D4T 3 10.00
 EFV+3TC+TDF 10 33.33
 NVP+3TC+AZT 9 30.00
 NVP+3TC+TDF 1 3.33
CD4 mean ± SDcells/μL 203 ± 133
ALT mean ± SDU/L 30.57 ± 13.13
AST mean ± SDU/L 29.87 ± 11.81
TBILmean ±SDμmol/L 15.40 ± 15.44
LEE was observed after cART (months)
 0-1 18 60.00
 1-3 7 23.33
 3-6 3 10.00
 6- 2 6.67
LEE was observed after cART (month, mean ± SD) 3.6 ± 7.5

Table 1: Demographic and clinical characteristics of the patients with hepatotoxicity at baseline.

LEE was observed in the majority of subjects (60%) within 1 month of start of cART. After 1-3 months of cART, 7 (23.33%) patients developed LEE (Table 1). The initial cART regimens are listed in Tables 1 and 2. Except cART hepatotoxicity, other reasons could also cause hepatotoxicity, such as alcohol abuse or fatty degeneration of liver. When hepatotoxicity reached grade 2 or more in these patients and we excluded other reasons, we changed their regimens (Table 2). In the initial regimens (first-line regimens), 66.67% patients used EFVcontaining regimens and 33.33% used NVP-containing regimens (Table 1). In the new regimens (second-line regimens), we replaced NVP or EFV with Lopinavir and Ritonavir tablets (LPV/r) in all cases.

Patient Number Initial Regimens New Regimens LEE observed (months)
1 EFV+3TC+D4T LPV/r+3TC+TDF 4
2 EFV+3TC+D4T LPV/r+3TC+TDF 1
3 NVP+3TC+AZT LPV/r+3TC+TDF 0.5
4 NVP+3TC+AZT LPV/r+3TC+TDF 0.5
5 EFV+3TC+TDF LPV/r+3TC+TDF 1
6 EFV+3TC+TDF LPV/r+3TC+TDF 1
7 EFV+3TC+AZT LPV/r+3TC+TDF 24
8 NVP+3TC+AZT LPV/r+3TC+TDF 0.5
9 EFV+3TC+TDF LPV/r+3TC+TDF 1
10 EFV+3TC+TDF LPV/r+3TC+TDF 6
11 NVP+3TC+TDF LPV/r+3TC+TDF 1
12 EFV+3TC+AZT LPV/r+3TC+TDF 6
13 EFV+3TC+D4T LPV/r+3TC+TDF 36
14 EFV+3TC+AZT LPV/r+3TC+TDF 1
15 EFV+3TC+TDF LPV/r+3TC+TDF 2
16 NVP+3TC+AZT LPV/r+3TC+AZT 1
17 NVP+3TC+AZT LPV/r+3TC+AZT 0.5
18 NVP+3TC+AZT LPV/r+3TC+TDF 1
19 EFV+3TC+AZT LPV/r+3TC+TDF 3
20 NVP+3TC+AZT LPV/r+3TC+AZT 2
21 EFV+3TC+AZT LPV/r+3TC+TDF 3
22 EFV+3TC+TDF LPV/r+3TC+TDF 0.5
23 EFV+3TC+TDF LPV/r+3TC+TDF 1
24 EFV+3TC+TDF LPV/r+3TC+TDF 2
25 NVP+3TC+AZT LPV/r+3TC+TDF 3
26 EFV+3TC+TDF LPV/r+3TC+TDF 1
27 NVP+3TC+AZT LPV/r+3TC+TDF 0.5
28 EFV+3TC+AZT LPV/r+3TC+TDF 1
29 EFV+3TC+AZT LPV/r+3TC+TDF 2
30 EFV+3TC+TDF LPV/r+3TC+TDF 1

Table 2: Initial and new regimens because of hepatotoxicity.

Comparison of liver function before and after the initial and new regimens

Because LEE is a marker for hepatotoxicity, we monitored alanine transaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBIL) respectively, before and after the initial cART regimens, and after the new regimens. Table 3 lists the results. Before beginning cART, values for ALT, AST and TBIL in most patients were normal or slightly higher than normal. After start of initial cART regimens, significant elevations of ALT and AST were observed, and a small increase in TBIL was found in most of these patients. When hepatotoxicity reached grade 2 or more in these patients and we excluded other reasons, we changed their regimens. After the new regimens were applied, ALT, AST and TBIL values were continued to monitor after the first month, the second month and the sixth month. Within six months, the patients’ ALT, AST and TBIL gradually returned back to normal levels. The values of ALT, AST and TBIL were also statistically compared. Liver function improved after one, two or six months of the application of new regimens, as shown in our statistical analyses (Table 4 and Figure 2). Thus, our data indicated that the new regimens containing LPV/r can alleviate the hepatotoxicity caused by EFV and NVP.

  Grades Baseline (%) LEE exposed (%) 1 month (%) 2 months (%) 6 months (%)
ALT normal 23 (76.67) 12 (40.00) 12 (40.00) 21 (70.00)
  Grade 1 7 (23.33) 6 (20.00) 5 (16.67) 13 (43.33) 8 (26.67)
  Grade 2   14 (46.67) 9 (30.00) 4 (13.33) 1 (3.33)
  Grade 3   9 (30.00) 3 (10.00) 1 (3.33)  
  Grade 4   1(3.33) 1 (3.33)    
AST normal 25 (83.33) 3 (10.00) 11 (36.67) 16 (53.33) 23 (76.67)
  Grade 1 5 (16.67) 15 (50.00) 12 (40.00) 13 (43.33) 7 (23.33)
  Grade 2   5 (16.67) 5 (16.67)    
  Grade 3   5 (16.67) 1(3.33) 1 (3.33)  
  Grade 4   2 (6.67) 1(3.33)    
TBIL normal 23 (76.67) 16 (53.33) 11 (36.67) 15 (50.00) 18 (60.00)
  Grade 1 5 (16.67) 3 (10.00) 9 (30.00) 14 (46.67) 11(36.67)
  Grade 2   5 (16.67) 7 (23.33) 1 (3.33) 1(3.33)
  Grade 3 1 (3.33) 6 (20.00) 3 (10.00)    
  Grade 4 1 (3.33)        

Table 3: ALT, AST and TBIL at baseline, at the time of elevation and 1, 2, 6 months of the application of new regimens (percent).

Figure 2: ALT, AST and TBIL at baseline, at the time of elevation and 1, 2, 6 months of the application of new regimens.

  Time Mean ± SD P value
ALT LEE exposed 191.37 ± 157.42  
  1 months 107.5 ± 102.23 0.000
  2 months 67.27 ± 56.015 0.014
  6 months 41.43 ± 24.77 0.000
AST LEE exposed 146.83 ± 164.89  
  1 month 86.37 ± 103.87 0.000
  2 months 52.87 ± 59.56 0.05
  6 months 37.67 ± 7.74 0.217
TBIL LEE exposed 25.41 ± 20.89  
  1 month 22.2 ± 10.12 0.624
  2 months 16.64 ± 4.73 0.017
  6 months 16.7 ± 4.04 0.909

Table 4: Non-parametric test- Wilcoxon test.

Notably, after the change of regimens and several months’ of treatment on the new regimen, the patients’ CD4+ cell counts significantly increased from 203 to 437 cells/μL (Table 5). None of patients died from hepatotoxicity.

  Baseline CD4 cell count
(n=30)
CD4 cell count after the treatment (n=30)  P (T test)
Patients 203 ± 133 cells/μL 437 ± 207 cells/μL 0.000

Table 5: CD4 cell count before and after the cART treatment.

The mean level of ALT and AST was 191.37 U/L and 146.83 U/L, respectively after cART exposure, but returned to normal after switching to new regimens.

The mean level of TBIL was 25.41 μmol/L. Values returned to normal two months after switching to new regimens.

Discussion

In this retrospective cohort study, 2270 HBV, HCV negative and HIV positive patients were followed for six years (13334.8 personyears). cART-related hepatotoxicity was well-controlled, and the incidence of liver-related death was zero percent. 67 cases (3.0% or 5.0 per 1000 person-years) died of non liver-related diseases, such as PCP, cryptococcal encephalitis etc. Of 2270 patients, only 30 cases (1.3%, or 2.2 per 1000 person-years) developed LEE, mostly as a consequence of cART-related hepatotoxicity. The cART regimens of these 30 cases contained EFV and NVP. These regimens were then replaced with LPV/r-containing regimens, and the patients’ liver functions progressively improved over the subsequent 6 months. LEE was mainly observed during the first 3 months of initial treatment with EFV- or NVP-containing regimens. Due to increased risk of fatal events, cART should be stopped in patients with grade 3-4 hepatotoxicity. After observing LEE in the patients, we changed their regimens. No patients died during the follow-up of this study. This finding was very similar to the French Mortavic study in 2005, in which 48 of 287 deaths (17%) in HIV-positive individuals were related to end-stage liver disease, and only 3 of 48 persons were HCV/HBV-negative [6,9].

In HIV-positive patients without HCV- or HBV- co-infection, limited data was available on liver-related mortality. In the large population-based National Health and Nutrition Examination Survey (NHANES) III study in the United States, mortality of persons with chronic HCV infection was 4.4 (1.5-12.9) per 1000 person-years [13], but liver-related mortality in HCV-negative individuals was 0.16 (95% CI, 0.10-0.25) per 1000 person years. Compared to the NHANES, our findings were zero percent among HIV-positive individuals without HCV or HBV co-infection. The reasons for this difference could be the limited cases in this study or well-managed cART regimens for the patients with high-grade hepatotoxicity.

Some studies showed that exposure to nucleoside reverse transcriptase inhibitors (NRTIs), particularly to the dideoxynucleosides (didanosine and zalcitabine), was related to the inhibition of mitochondrial DNA γ-polymerase, leading to severe hyperlactatemia and high mortality rate [14,15]. Thus, in China, these drugs are no longer recommended in the cART regimens.

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) EFV and NVP, are widely used in China today, which can cause hepatotoxicity. Especially, NVP is associated with an increased risk of acute hepatotoxicity. According to national guideline [12], NVP is not used in patients with baseline CD4 cell count >250 cells/μL. Wang J et al. [16] reported that hepatotoxicity was significantly associated with the median NVP trough concentrations among male patients, as well as HCV- co-infection. Our study was in agreement with these findings. We have observed gradual improvement in patients’ liver function after replacing EFV or NVP with LPV/r.

In some reports, the prevalence of severe alcohol use in HIV positive individuals ranges from 2.8% to 35%, depending on the observed population [17-20]. However, in this study, we didn’t find any death related to alcoholic liver disease. We talked to the 30 patients who developed hepatotoxicity, and nobody reported severe alcohol use (60 g/d). This could be the life style of these patients. We also found that many patients in this cohort were MSM patients. In Tianjin and other big cites in China, MSM patients are now becoming the main population infected with HIV. They usually have good educational background and are less at risk of alcohol abuse. However, this remains speculative because of the low number of patients and this need to be further investigated.

The strength of this study is the focus on population of hepatotoxicity without hepatitis virus co-infections in Tianjin, representing other big cities of China. Limitations are that we didn’t report other cART-related side effects, which will be reported in other studies. In addition, patients totally lost in this cohort are unlikely to be on cART treatment. These missed cases are unlikely to contribute to rates of cART-related LEE.

Conclusion

In conclusion, this study provides evidence that cART-related hepatotoxicity can be controlled and managed by modifying the treatment regimens. Currently, the United States Food and Drug Administration (FDA) have approved more than 20 anti-HIV agents, and more options will likely be available in the future. In China, free cART only includes 8 therapeutic agents. Considering the risks and side effects associated with these medications, we hope that many HIVinfected patients in China will benefit from the future inclusion of additional agents in the free cART program.

Lay Summary

Hepatotoxicity caused by cART in HIV-infected patients should be monitored. Once liver function markers, such as alanine transaminase (ALT), aspartate transaminase (AST), are found higher than normal, the cART regimens should be changed accordingly to avoid the further hepatotoxicity and death to the patients.

Acknowledgement

We thank Professor Fusheng Wang, an academician of Chinese Academy of Sciences, for critically reading the manuscript. We also thank Dr. Cameron McKay for proofreading and Dr. Meiying Zhang for statistical analyses.

Financial Support Statement

Science and Technology Foundation of Tianjin Health Bureau (2014KR03 to PM).

Author Contributions

PM, JQ and LG designed the study and decided the therapeutic regimens. DZ, AY and CQ performed the treatment to the patients and enter the data to the databank. PM and MW collected and analyzed the data. PM and MW wrote the paper.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 6th International Conference on HIV/AIDS , STDs and STIs
    October 29-30, 2018 San Francisco, USA
  • 7th International Conference on HIV/AIDS, STDs and STIs
    March 18-19, 2019 New York, USA

Article Usage

  • Total views: 443
  • [From(publication date):
    August-2017 - Sep 18, 2018]
  • Breakdown by view type
  • HTML page views : 412
  • PDF downloads : 31
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version